Tianjin TEDA Biomedical Engineering Company Limited

Symbol: 8189.HK

HKSE

0.068

HKD

Market price today

  • -5.7818

    P/E Ratio

  • 0.0135

    PEG Ratio

  • 118.41M

    MRK Cap

  • 0.00%

    DIV Yield

Tianjin TEDA Biomedical Engineering Company Limited (8189-HK) Stock Price & Analysis

Shares Outstanding

2124.7M

Gross Profit Margin

0.05%

Operating Profit Margin

-0.05%

Net Profit Margin

-0.06%

Return on Assets

-0.07%

Return on Equity

-0.33%

Return on Capital Employed

-0.21%

Company general description and statistics

Sector: Basic Materials
Industry: Agricultural Inputs
CEO:Ms. Li Sun
Full-time employees:264
City:Tianjin
Address:Tianda Hi-Tech Park
IPO:2002-06-18
CIK:

Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. The company operates in two segments, Biological Compound Fertilizers Products, and Elderly Care and Health Care Services. Its biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formula that are used for the facilitation of balanced growth of grains, fruits, and vegetables. The company is also involved in the provision of integrated elderly and health care; and elderly equipment leasing services, as well as consulting, advisory, and assessment services. In addition, it provides and licenses electroencephalography photography (EEG) diagnosis detection services; and conducts EEG detection and diagnosis technology services. Further, the company engages in the research, development, manufacture, and application of biomedical science and technology projects; regional soil resources conditioning and remediation business; and provision of soil environmental quality standards research services. Tianjin TEDA Biomedical Engineering Company Limited was incorporated in 2000 and is headquartered in Tianjin, the People's Republic of China.

General Outlook

In simple terms, Tianjin TEDA Biomedical Engineering Company Limited has 2124.697 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.054% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.045%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.055%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.073% return, is a testament to Tianjin TEDA Biomedical Engineering Company Limited's adeptness in optimizing resource deployment. Tianjin TEDA Biomedical Engineering Company Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.332%. Furthermore, the proficiency of Tianjin TEDA Biomedical Engineering Company Limited in capital utilization is underscored by a remarkable -0.208% return on capital employed.

Stock Prices

Tianjin TEDA Biomedical Engineering Company Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.082, while its low point bottomed out at $0.082. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Tianjin TEDA Biomedical Engineering Company Limited's stock market.

Liquidity Ratios

Analyzing 8189.HK liquidity ratios reveals its financial health of the firm. The current ratio of 87.78% gauges short-term asset coverage for liabilities. The quick ratio (6.78%) assesses immediate liquidity, while the cash ratio (2.74%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio87.78%
Quick Ratio6.78%
Cash Ratio2.74%

Profitability Ratios

8189.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -3.02% underscores its earnings before tax deductions. The effective tax rate stands at 7.20%, revealing its tax efficiency. The net income per EBT, 183.06%, and the EBT per EBIT, 66.83%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -4.52%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-3.02%
Effective Tax Rate7.20%
Net Income per EBT183.06%
EBT per EBIT66.83%
EBIT per Revenue-4.52%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.88, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding7
Days of Inventory Outstanding88
Operating Cycle95.71
Days of Payables Outstanding16
Cash Conversion Cycle80
Receivables Turnover45.35
Payables Turnover23.38
Inventory Turnover4.16
Fixed Asset Turnover3.99
Asset Turnover1.31

Cash Flow Ratios

Lastly, the operating cash flow sales ratio, 0.01, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow Sales Ratio0.01
Free Cash Flow to Operating Cash Flow Ratio0.33
Cash Flow Coverage Ratio0.03
Short Term Coverage Ratio0.03
Capital Expenditure Coverage Ratio1.49
Dividend Paid and Capex Coverage Ratio1.49

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 27.55%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.67, we discern the balance between debt and equity financing. The long-term debt to capitalization, 28.89%, and total debt to capitalization, 62.59%, ratios shed light on its capital structure. An interest coverage of -3.47 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio27.55%
Debt Equity Ratio1.67
Long Term Debt to Capitalization28.89%
Total Debt to Capitalization62.59%
Interest Coverage-3.47
Cash Flow to Debt Ratio0.03
Company Equity Multiplier6.07

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.21, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.01, reflects the portion of profit attributed to each share. The book value per share, 0.03, represents the net asset value distributed per share, while the tangible book value per share, 0.03, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.21
Net Income Per Share-0.01
Book Value Per Share0.03
Tangible Book Value Per Share0.03
Shareholders Equity Per Share0.03
Interest Debt Per Share0.05

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -11.49%, indicates top-line expansion, while the gross profit growth, 30.32%, reveals profitability trends. EBIT growth, 7.06%, and operating income growth, 7.06%, offer insights into operational profitability progression. The net income growth, 24.34%, showcases bottom-line expansion, and the EPS growth, 24.82%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-11.49%
Gross Profit Growth30.32%
EBIT Growth7.06%
Operating Income Growth7.06%
Net Income Growth24.34%
EPS Growth24.82%
EPS Diluted Growth24.82%
Operating Cash Flow Growth-2.60%
Free Cash Flow Growth27.73%
10-Year Revenue Growth per Share-48.84%
5-Year Revenue Growth per Share10.75%
3-Year Revenue Growth per Share7.75%
10-Year Operating CF Growth per Share7.44%
5-Year Operating CF Growth per Share41.02%
3-Year Operating CF Growth per Share-136.55%
10-Year Net Income Growth per Share-170.69%
5-Year Net Income Growth per Share88.89%
3-Year Net Income Growth per Share59.97%
10-Year Shareholders Equity Growth per Share-81.41%
5-Year Shareholders Equity Growth per Share-82.08%
3-Year Shareholders Equity Growth per Share-65.08%
Receivables Growth-72.46%
Inventory Growth22.23%
Asset Growth-10.06%
Book Value per Share Growth-31.27%
Debt Growth-12.97%
R&D Expense Growth16.09%
SGA Expenses Growth-20.23%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 247,573,652.05, captures the company's total value, considering both debt and equity. Income quality, 0.75, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.05, gauges operational efficiency, while the research and development to revenue, 0.33%, highlights investment in innovation. The ratio of intangibles to total assets, 4.38%, indicates the value of non-physical assets, and capex to operating cash flow, 18.77%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value247,573,652.05
Income Quality0.75
Sales General and Administrative to Revenue0.05
Research and Development to Revenue0.33%
Intangibles to Total Assets4.38%
Capex to Operating Cash Flow18.77%
Capex to Revenue-0.62%
Capex to Depreciation-21.22%
Graham Number0.08
Return on Tangible Assets-6.95%
Graham Net Net-0.10
Working Capital-26,500,218
Tangible Asset Value51,310,798
Net Current Asset Value-48,356,554
Invested Capital2
Average Receivables20,321,643.5
Average Payables18,415,092
Average Inventory82,230,399.5
Days Sales Outstanding8
Days Payables Outstanding16
Days of Inventory On Hand88
ROIC-13.22%
ROE-0.40%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.55, and the price to book ratio, 2.55, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.29, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 164.79, and price to operating cash flows, 58.70, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.55
Price to Book Ratio2.55
Price to Sales Ratio0.29
Price Cash Flow Ratio58.70
Price Earnings to Growth Ratio0.01
Enterprise Value Multiple-3.96
Price Fair Value2.55
Price to Operating Cash Flow Ratio58.70
Price to Free Cash Flows Ratio164.79
Price to Tangible Book Ratio3.40
Enterprise Value to Sales0.62
Enterprise Value Over EBITDA142.88
EV to Operating Cash Flow-18.82
Earnings Yield-11.86%
Free Cash Flow Yield-9.19%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) on the HKSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.782 in 2024.

What is the ticker symbol of Tianjin TEDA Biomedical Engineering Company Limited stock?

The ticker symbol of Tianjin TEDA Biomedical Engineering Company Limited stock is 8189.HK.

What is company IPO date?

IPO date of Tianjin TEDA Biomedical Engineering Company Limited is 2002-06-18.

What is company current share price?

Current share price is 0.068 HKD.

What is stock market cap today?

The market cap of stock today is 118411891.000.

What is PEG ratio in 2024?

The current 0.013 is 0.013 in 2024.

What is the number of employees in 2024?

In 2024 the company has 264.